Neurocentria Inc v. MANDO Intl LLC

I. Executive Summary and Procedural Information

• Parties & Counsel:
  • Plaintiff: Neurocentria, Inc. (California) and Threotech LLC (Nevada)
  • Defendant: Mando International, LLC d/b/a Kappa Nutrition (Texas)
  • Plaintiff's Counsel: Fortis LLP; Barnes & Thornburg LLP; Hughes Hubbard & Reed LLP
• Case Identification: 2:25-cv-05871, C.D. Cal., 02/26/2026
• Venue Allegations: Venue is alleged to be proper based on a mandatory forum-selection clause in a Trademark License Agreement (TMLA) previously executed between the parties, which designated the United States Federal Court for the State of California for legal proceedings. The complaint also notes that the Defendant has conceded to proceed in the Central District of California.
• Core Dispute: Plaintiffs allege that Defendant's magnesium nutritional supplements infringe a patent related to dosage forms of magnesium L-threonate.
• Technical Context: The technology resides in the field of nutritional supplements, specifically chemical compositions designed to enhance magnesium bioavailability for improving cognitive health and addressing neurological disorders.
• Key Procedural History: The complaint states that the parties previously operated under a Trademark License Agreement (TMLA), which Plaintiff ThreoTech terminated on July 15, 2024, following an alleged breach by the Defendant. Plaintiffs allege that Defendant continued to sell infringing products after the agreement's termination and a subsequent six-month sell-down period expired.

Case Timeline

II. Technology and Patent(s)-in-Suit Analysis

U.S. Patent No. 8,637,061 - "Magnesium Compositions and Uses Thereof for Neurological Disorders"

The Invention Explained

• Problem Addressed: The patent's background section notes that while magnesium is essential for human health, dietary intake is often inadequate '061 Patent, col. 1:55-61 It further states that many existing commercial magnesium supplements have low bioavailability or cause undesirable side effects like diarrhea, creating a need for improved magnesium compositions '061 Patent, col. 2:5-23
• The Patented Solution: The invention provides compositions of magnesium, particularly magnesium threonate, formulated for administration to a subject to maintain or enhance cognitive and memory functions or treat neurological disorders '061 Patent, abstract The specification describes magnesium's role in synaptic plasticity and suggests that certain compositions can effectively deliver magnesium to achieve these benefits '061 Patent, col. 1:28-40 '061 Patent, col. 3:5-14
• Technical Importance: The invention addresses the challenge of delivering sufficient magnesium to the body and brain in a bioavailable form without significant side effects, a key technical hurdle in the development of effective nutritional supplements for cognitive health.

Key Claims at a Glance

• The complaint asserts infringement of at least independent claim 1 '061 Patent, col. 27:27-31 Compl. ¶70
• The essential elements of independent claim 1 are:
  • A dosage form formulated for oral administration to a subject
  • comprising magnesium threonate,
  • wherein the dosage form comprises at least 10 mg magnesium threonate, and
  • wherein the dosage form is a solid, semi-solid, semi-liquid, or a gel.
• The complaint reserves the right to assert infringement of other claims '061 Patent, col. 27:32-67 Compl. ¶75

III. The Accused Instrumentality

Product Identification

The complaint identifies two accused products: the "Magnesium L-Threonate 3 in 1 Advanced Complex" (referred to as the "Non-Licensed Product") and the "Magnesium L-Threonate Plant-Based product" (referred to as the "Plant-Based Product") Compl. ¶47 Compl. ¶54 Compl. ¶75

Functionality and Market Context

The accused products are oral dietary supplements sold in capsule form Compl. ¶48 Compl. ¶55 The complaint alleges that the product labels and marketing materials represent that the products contain Magnesium and L-Threonate and provide health benefits such as supporting brain health, memory, cognitive function, and sleep Compl. ¶¶50-51 Compl. ¶57 An image of the "Non-Licensed Product" label shows it contains an unspecified amount of "L-Threonate (as L-Threonic Acid)" per capsule Compl. ¶48 Compl. Fig. 2 An image of the "Plant-Based Product" label shows it contains an unspecified amount of "Magnesium L-Threonate (Plant-Based)" Compl. ¶55 Compl. Fig. 3 The products are allegedly sold through online channels, including Amazon Compl. ¶51

IV. Analysis of Infringement Allegations

'061 Patent Infringement Allegations

Identified Points of Contention

• Scope Questions: The complaint's infringement theory appears to rely on the premise that providing magnesium and L-Threonic acid as ingredients within a single capsule meets the claim limitation "comprising magnesium threonate" Compl. ¶¶71-73 A central legal question may be whether this claim language requires the pre-formed magnesium threonate salt to be present in the dosage form, or if it can be read to cover a composition containing the constituent components that can form the salt.
• Technical Questions: The allegation that the dosage form meets the "at least 10 mg" limitation is based on a calculation derived from a third-party lab analysis of the L-Threonic Acid content per capsule Compl. ¶¶71-73 An evidentiary question may arise regarding the accuracy of the lab test and the validity of the chemical conversion ratio (allegedly 91% to 92%) used to calculate the total amount of magnesium threonate formed Compl. ¶72

V. Key Claim Terms for Construction

The Term

"comprising magnesium threonate"

Context and Importance

The construction of this term is fundamental to the infringement analysis. The complaint's theory is that the accused products contain L-Threonic Acid and Magnesium which form a sufficient quantity of magnesium threonate Compl. ¶¶71-73 The case may turn on whether a product containing the precursor components, rather than the fully-reacted salt, falls within the scope of the claim. Practitioners may focus on this term because it addresses the state of the chemical composition as sold, which is a common point of dispute in chemical and pharmaceutical patent cases.

Intrinsic Evidence for Interpretation

• Evidence for a Broader Interpretation: The patent uses the term "magnesium-comprising component (MCC)" broadly in the specification, which could suggest an intent to cover various ways of delivering magnesium '061 Patent, col. 3:3-5 The use of the open-ended transition word "comprising" may support an interpretation that the claimed components can be present in various forms.
• Evidence for a Narrower Interpretation: The claim explicitly recites the specific chemical compound "magnesium threonate" rather than its constituent ions or precursors '061 Patent, col. 27:33 The specification also lists "magnesium threonate" as a distinct example among other magnesium salts like "magnesium citrate" and "magnesium lactate" '061 Patent, col. 3:7-10, which could suggest the drafters intended to refer to the specific, pre-formed compound.

VI. Other Allegations

Indirect Infringement

The complaint alleges both induced and contributory infringement. It alleges inducement based on Defendant's dosage instructions on product labels and marketing materials, which allegedly instruct and encourage customers to use the products in an infringing manner Compl. ¶¶97-98 It alleges contributory infringement on the basis that the components are not staple articles of commerce and are specifically adapted for the infringing use Compl. ¶86

Willful Infringement

The complaint alleges willful infringement based on Defendant's pre-suit knowledge of the '061 Patent. This knowledge is allegedly established by the Defendant's own product label for its previously licensed product, which explicitly listed several "Magtein Patents," including patents from the same family as the '061 Patent Compl. ¶23 Willfulness is also alleged based on continued sales after the termination of the TMLA Compl. ¶79

VII. Analyst's Conclusion: Key Questions for the Case

• A core issue will be one of definitional scope: can the claim term "comprising magnesium threonate" be construed to cover a product that contains magnesium and L-threonic acid as separate or unreacted ingredients within a single dosage form, or does it strictly require the pre-formed magnesium threonate salt?
• A key evidentiary question will be one of factual composition: does the complaint's reliance on a lab test and subsequent chemical calculation provide sufficient proof that the accused products actually contain "at least 10 mg" of the claimed "magnesium threonate" compound per capsule, and will the methodology and results of this analysis withstand scrutiny?